Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T‑Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024;332(22):1924–35. https://doi.org/10.1001/jama.2024.19462.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379(1):64–73. https://doi.org/10.1056/NEJMra1706169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–71. https://doi.org/10.1038/s41571-023-00754-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller F, Taubmann J, Bucci L, et al. CD19 CAR T‑Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024;390(8):687–700. https://doi.org/10.1056/NEJMoa2308917.

Article  PubMed  Google Scholar 

Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B‑cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3):279–86. https://doi.org/10.1038/nm827.

Article  CAS  PubMed  Google Scholar 

Shaikh S, Shaikh H. CART Cell Therapy Toxicity. In: StatPearls. StatPearls Publishing. 2026. http://www.ncbi.nlm.nih.gov/books/NBK592426/. Accessed 4 Apr 2026.

Maleki S, Esmaeili Z, Seighali N, et al. Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis. Cardio-Oncol. 2024;10(1):52–52. https://doi.org/10.1186/s40959-024-00252-y.

Article  Google Scholar 

T J, J S, A A, L Z, RA S, TQ D. Cardiotoxic Effects Following CAR‑T Cell Therapy: A Literature Review. Curr Oncol Rep. 2025;27(2):135–47. https://doi.org/10.1007/s11912-024-01634-2.

Article  Google Scholar 

Munir M, Sayed A, Addison D, Epperla N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 2024;8(24):6282–96. https://doi.org/10.1182/bloodadvances.2024013849.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T‑Cell Therapy in Refractory Large B‑Cell Lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalal PJ, Patel NP, Feinstein MJ, Akhter N. Adverse Cardiac Effects of CAR T‑Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. Technol Cancer Res Treat. 2022;21:15330338221132927. https://doi.org/10.1177/15330338221132927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed/refractory adult B‑cell acute lymphoblastic leukemia: phase 2 results from the single-arm, multicenter ZUMA‑3 study. Lancet. 2021;398(10299):491–502. https://doi.org/10.1016/S0140-6736(21)01222-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B‑cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52. https://doi.org/10.1016/S0140-6736(20)31366-0.

Article  CAS  PubMed  Google Scholar 

Lee DH, Kumar A, Mohammed T, et al. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023;7(16):4247–57. https://doi.org/10.1182/bloodadvances.2023009766.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheikh F, Ross RS, Chen J. Cell-cell connection to cardiac disease. Trends Cardiovasc Med. 2009;19(6):182–90. https://doi.org/10.1016/j.tcm.2009.12.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

CRS and ICANS | AUCATZYL® (obecabtagene autoleucel) HCP Site. AUCATZYL® (obecabtagene autoleucel) HCP Website. Accessed August 17, 2025. https://www.aucatzylhcp.com/safety/crs-and-icans/

Adkins S. CAR T‑Cell Therapy: Adverse Events and Management. J Adv Pract Oncol. 2019;10(Suppl 3):21–8. https://doi.org/10.6004/jadpro.2019.10.4.11.

Article  PubMed  PubMed Central  Google Scholar 

Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR‑T cell therapy. Biomark Res. 2018;6:4. https://doi.org/10.1186/s40364-018-0116-0.

Article  PubMed  PubMed Central  Google Scholar 

Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11(1 Suppl):37–42. https://doi.org/10.1188/07.CJON.S1.37-42.

Article  PubMed  Google Scholar 

Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–e7. https://doi.org/10.1016/j.bbmt.2018.12.756.

Article  CAS  PubMed  Google Scholar 

Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. https://doi.org/10.1056/NEJMoa1215134.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B‑cell lymphoma. Haematologica. 2021;106(4):978–86. https://doi.org/10.3324/haematol.2019.238634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49–62. https://doi.org/10.1038/s41571-022-00704-3.

Article  CAS  PubMed  Google Scholar 

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther J Am Soc Gene Ther. 2010;18(4):843–51. https://doi.org/10.1038/mt.2010.24.

Article  CAS  Google Scholar 

Garcia Borrega J, Gödel P, Rüger MA, et al. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR‑T Cell Therapy. HemaSphere. 2019;3(2)e191. https://doi.org/10.1097/HS9.0000000000000191.

Article  PubMed  PubMed Central  Google Scholar 

Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197)197ra103. https://doi.org/10.1126/scitranslmed.3006034.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–71. https://doi.org/10.1182/blood-2013-03-490565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gust J, Hay KA, Hanafi LA, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR‑T Cells. Cancer Discov. 2017;7(12):1404–19. https://doi.org/10.1158/2159-8290.CD-17-0698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B‑cell maturation antigen-directed chimeric antigen receptor T‑cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. https://doi.org/10.1016/S0140-6736(21)00933-8